ERHUI 1979/Getty Images October 6, 2025 An Abundant Blindspot The warping, smothering influence of corporate money and power lurks on every page unacknowledged, a monster Klein and Thompson refuse to see. David Watkins Director of Government Affairs, Climate & Energy Program
Lilly Adams/UCS October 6, 2025 After Decades, Relief for Some Harmed by the Nuclear Weapons Industry Lilly Adams Senior Outreach Coordinator
October 2, 2025 The Big Winners in California? Science and Climate. Daniel Barad Western States Policy Manager
April 13, 2012 How Conflicted Experts Can Sway FDA Drug Approval Decisions: A Case Study on Yaz Francesca Grifo Former contributor
April 11, 2012 The Human Cost of FDA Decisions: For Dan and Elsa, Life Depends on Safe Medical Devices Michael Halpern Former Contributor
April 11, 2012 On the Road to Clean Energy in Germany: Lessons for the United States – Part 3 Steve Clemmer Director of Energy Research & Analysis
April 11, 2012 Reflections on the Seoul Nuclear Security Summit Ed Lyman Director, Nuclear Power Safety
April 10, 2012 The Human Cost of FDA Decisions: For a Midwestern Family, A Breakdown in Drug Safety Hits Home Michael Halpern Former Contributor
April 10, 2012 Fission Stories #87: NRC Resolves Humongous Nuclear Safety Problem Dave Lochbaum Former Contributor
April 9, 2012 Five Good Reasons to Eat Food (and One Not-So-Good One) Doug Boucher Former Contributor
April 5, 2012 On the Road to Clean Energy in Germany: Lessons for the United States – Part 2 Jeff Deyette Director of State Policy and Analysis
April 4, 2012 China in Focus #4: “Strategic Distrust” and Climate Change Gregory Kulacki East Asia Project Manager
April 3, 2012 New Allegations of Political and Corporate Pressure on FDA Michael Halpern Former Contributor
April 3, 2012 On the Road to Clean Energy in Germany: Lessons for the United States – Part 1 Jeff Deyette Director of State Policy and Analysis